Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan.
Cytotoxic T lymphocyte
Endocan
Epitopes
HLA-A*0201
Journal
Journal of inflammation (London, England)
ISSN: 1476-9255
Titre abrégé: J Inflamm (Lond)
Pays: England
ID NLM: 101232234
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
11
2019
accepted:
11
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
27
2
2020
Statut:
epublish
Résumé
Prediction and identification of cytotoxic T lymphocyte (CTL) epitopes from tumor associated antigens is a crucial step for the development of tumor immunotherapy strategy. Endocan has been identified as antigen overexpressed in various tumors. In this experiment, we predicted and identified HLA-A2-restricted CTL epitopes from endocan by using the following procedures. Firstly, we predicted the epitopes from the amino acid sequence of endocan by computer-based methods; Secondly, we determined the affinity of the predicted peptide with HLA-A2.1 molecule by peptide-binding assay; Thirdly, we elicited the primary T cell response against the predicted peptides in vitro; Lastly, we tested the specific CTLs toward endocan and HLA-A2.1 positive target cells. These data demonstrated that peptides of endocan containing residues 4-12 and 9-17 could elicit specific CTLs producing interferon-γ and cytotoxicity. Therefore, our findings suggested that the predicted peptides were novel HLA-A2.1-restricted CTL epitopes, and might provide promising target for tumor immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Prediction and identification of cytotoxic T lymphocyte (CTL) epitopes from tumor associated antigens is a crucial step for the development of tumor immunotherapy strategy. Endocan has been identified as antigen overexpressed in various tumors.
METHODS
METHODS
In this experiment, we predicted and identified HLA-A2-restricted CTL epitopes from endocan by using the following procedures. Firstly, we predicted the epitopes from the amino acid sequence of endocan by computer-based methods; Secondly, we determined the affinity of the predicted peptide with HLA-A2.1 molecule by peptide-binding assay; Thirdly, we elicited the primary T cell response against the predicted peptides in vitro; Lastly, we tested the specific CTLs toward endocan and HLA-A2.1 positive target cells.
RESULTS
RESULTS
These data demonstrated that peptides of endocan containing residues 4-12 and 9-17 could elicit specific CTLs producing interferon-γ and cytotoxicity.
CONCLUSIONS
CONCLUSIONS
Therefore, our findings suggested that the predicted peptides were novel HLA-A2.1-restricted CTL epitopes, and might provide promising target for tumor immunotherapy.
Identifiants
pubmed: 32099535
doi: 10.1186/s12950-020-00240-w
pii: 240
pmc: PMC7031931
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Int J Cell Biol. 2013;2013:705027
pubmed: 23606845
J Mol Med (Berl). 2017 May;95(5):553-564
pubmed: 28083623
J Neurooncol. 2014 May;117(3):485-91
pubmed: 24504498
Int J Cancer. 2018 Jan 1;142(1):176-190
pubmed: 28884474
Cancer Cell Int. 2015 Jun 05;15:57
pubmed: 26146488
Breast Cancer Res Treat. 2017 Jan;161(2):269-278
pubmed: 27888420
Brain Pathol. 2012 Nov;22(6):757-64
pubmed: 22353248
Cancer Gene Ther. 2017 Jul;24(7):289-296
pubmed: 28621316
J Cell Biochem. 2011 Dec;112(12):3685-94
pubmed: 21815198
Cancer Immunol Immunother. 2016 Nov;65(11):1303-1315
pubmed: 27520505
Oncoimmunology. 2015 Dec 10;5(4):e1093276
pubmed: 27141377
J Thromb Thrombolysis. 2017 Jan;43(1):60-67
pubmed: 27638814
Clin Cancer Res. 2018 Aug 15;24(16):3955-3966
pubmed: 29712687
Angiology. 2017 Jan;68(1):80
pubmed: 27581070
Prog Neurol Surg. 2018;32:79-89
pubmed: 29990976
Cancer Res Treat. 2019 Apr;51(2):464-473
pubmed: 29879758
Prog Neurol Surg. 2018;31:1-37
pubmed: 29393190
Mol Immunol. 2010 Jul;47(11-12):1963-73
pubmed: 20546900
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150
pubmed: 28815663
Onco Targets Ther. 2016 Oct 13;9:6297-6304
pubmed: 27785077
Cancer Immunol Immunother. 2018 Feb;67(2):237-246
pubmed: 29058035
Mol Immunol. 2013 Sep;55(2):143-5
pubmed: 23158834
Cell Immunol. 2011;272(1):102-6
pubmed: 22032907
Oncogene. 2017 Sep 21;36(38):5356-5368
pubmed: 28534507
J Appl Physiol (1985). 2019 Sep 1;127(3):668-678
pubmed: 31295063
Tumour Biol. 2016 Nov;37(11):14915-14921
pubmed: 27644250
PLoS One. 2013 Dec 05;8(12):e82254
pubmed: 24340011
Prog Neurol Surg. 2018;32:66-78
pubmed: 29990975
Prog Neurol Surg. 2018;32:101-111
pubmed: 29990978
Oncotarget. 2015 Feb 20;6(5):2725-35
pubmed: 25575808
Clin Cancer Res. 2006 Aug 1;12(15):4575-82
pubmed: 16899604
J Neuroimmunol. 2012 Jan 18;242(1-2):9-15
pubmed: 22123613
Cancer Lett. 2017 Dec 28;411:182-190
pubmed: 28947140
Indian J Pharmacol. 2014 Nov-Dec;46(6):579-83
pubmed: 25538326
Prog Neurol Surg. 2018;32:180-195
pubmed: 29990984
Prog Neurol Surg. 2018;32:159-171
pubmed: 29990982
Prog Neurol Surg. 2018;32:124-151
pubmed: 29990980
Nat Commun. 2018 May 18;9(1):1991
pubmed: 29777137
Oncol Lett. 2017 Nov;14(5):5333-5339
pubmed: 29113167
J Periodontol. 2017 May;88(5):493-501
pubmed: 27976595
Cancer Res. 2013 Feb 1;73(3):1097-106
pubmed: 23243026
Cancer Res. 2017 Dec 1;77(23):6692-6703
pubmed: 28986380
Clin Lab. 2018 Mar 1;64(3):405-410
pubmed: 29739097
Methods Mol Biol. 2018;1709:359-369
pubmed: 29177672
Science. 2018 Apr 20;360(6386):331-335
pubmed: 29674595
Nat Med. 2018 May;24(5):572-579
pubmed: 29662203
Mol Carcinog. 2018 Sep;57(9):1181-1190
pubmed: 29745440
Oncoimmunology. 2016 Mar 16;5(6):e1163461
pubmed: 27471637
Prog Neurol Surg. 2018;31:180-199
pubmed: 29393186
Microvasc Res. 2006 Nov;72(3):136-45
pubmed: 16956626